ZLDPF Zealand Pharma A/S

Zealand Pharma to participate in the Jefferies London Healthcare Conference

Zealand Pharma to participate in the Jefferies London Healthcare Conference

Press Release – No. 11 / 2024

Zealand Pharma to participate in the Jefferies London Healthcare Conference

Copenhagen, Denmark, November 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Jefferies London Healthcare Conference at 9:30 a.m. GMT (10:30 a.m. CET) on Thursday, November 21, 2024.

A live audio webcast of the fireside chat will be available at and accessible through the company’s website at where a recording of the webcast will also be archived after the event.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit .

Contacts:

Anna Krassowska, PhD

Vice President, Investor Relations & Corporate Communications

Zealand Pharma

Email:

Adam Lange

Investor Relations Officer

Zealand Pharma

Email:

Neshat Ahmadi

Investor Relations Manager

Zealand Pharma

Email:



EN
13/11/2024

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

Zealand Pharma Initiation: Shifting pounds into profit

Zealand is a Danish biotech with a broad pipeline in obesity and rare disease. Petrelintide (amylin analog) could become a monotherapy challenger to GLP-1 drugs based on its efficacy and tolerability in phase 1b, and phase 2b results in 2026 could set petrelintide up to capture a significant share of the $140b obesity market as the go to option for GLP-1 intolerant patients, weight loss maintenance and beyond. In addition, survodutide (GLP-1/glucagon analog) is already out-licenced to BI with on...

ZLDPF ZEALAND PHARMA A/S
11/20/24 November 20, 2024 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma to participate in the Jefferies London Healthcare Confe...

Zealand Pharma to participate in the Jefferies London Healthcare Conference Press Release – No. 11 / 2024 Zealand Pharma to participate in the Jefferies London Healthcare Conference Copenhagen, Denmark, November 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Jefferies London Healthcare Conference at 9:30 a.m. GMT (10:30 a.m. CET) on Thursday, November 21, 2024. A liv...

November 13, 2024 1 EN
Free Trial
ZLDPF Zealand Pharma ...

Zealand Pharma AS: 1 director

A director at Zealand Pharma AS sold 1,500 shares at 849.000DKK and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

ZLDPF ZEALAND PHARMA A/S
11/12/24 November 12, 2024 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma Announces Financial Results for the First Nine Months o...

Zealand Pharma Announces Financial Results for the First Nine Months of 2024 Company announcement – No. 49 / 2024 Zealand Pharma Announces Financial Results for the First Nine Months of 2024 Continued strong progress across obesity pipeline with proprietary assets ready for Phase 2 backed by a solid financial position.   Presented extremely encouraging weight loss and tolerability data with long-acting amylin analog petrelintide from MAD Part 2 (16-week trial) at ObesityWeek 2024Announced positive topline results with GLP-1R/GLP-2R dual agonist dapiglutide from Part 1 of Phase 1b trial ...

November 7, 2024 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to pr...

Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Press Release – No. 10 / 2024 Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Copenhagen, Denmark, November 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on November 7, 2024, at 2:00 pm CET (8:00 am ET) following the announcement...

November 1, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch